Thomas Jens Ettrich

33PUBLICATIONS
115CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersReaction engineering (excl. nuclear reactions)Other law and legal studies not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jun 10, 2026
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.

|Apr 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

|Feb 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience

|Oct 14, 2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Manfred P Lutz, Nikolaus Ansorge, Gleb Barmashenko

|May 27, 2025
[Correction: Version 3.1].

Thomas Seufferlein, Julia Mayerle, Stefan Boeck

|May 27, 2025
[Correction: AWMF-Registernummer: 032-010OL - Leitlinie (Kurzversion)].

Thomas Seufferlein, Julia Mayerle, Stefan Boeck

Pageof 6

Frequent Collaborators

6 joint publications

Angelika Kestler

5 joint publications

Sylvie Lorenzen

5 joint publications

Lukas Perkhofer

3 joint publications

Maria Loose